Literature DB >> 6229475

Defective repertoire of proliferative T cells during lymphatic regeneration.

M Sihvola, M Hurme.   

Abstract

Proliferative T cell responses against syngeneic (SMLC) and allogeneic (alloMLC) non-T cells were investigated during the splenic regeneration after an injection of a sublethal dose (300 mg/kg) of cyclophosphamide (Cy). Two days after Cy injection spleen contained no cells capable of proliferative responses. T cells from the regenerating spleens (on day 6-8) had a defective proliferative capacity: the reactivity in the SMLC was at the normal level while alloreactivity was negative. The alloMLC appeared by 14 days after Cy injection, and it was still lower than the alloMLC of the normal splenic T cells. Responding cells of the SMLC in the regenerating phase belonged to the Ly-1+2- cell population: anti-Ly-1 antibody + complement (C) diminished the SMLC by 80%, anti-Ly-2 antibody + C had no effect on the responsiveness of the regenerating T cells. The stimulation of this SMLC was less dependent on splenic adherent cells than the normal SMLC. The significance of these data to the origin of alloreactivity and to the role of the SMLC in the cytotoxic T cell responses are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229475      PMCID: PMC1454444     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

Review 1.  The somatic generation of immune recognition.

Authors:  N K Jerne
Journal:  Eur J Immunol       Date:  1971-01       Impact factor: 5.532

2.  Killer cells reactive to altered-self antigens can also be alloreactive.

Authors:  M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Selective stimulation by B lymphocytes in the syngeneic mixed lymphocyte reaction.

Authors:  H Von Boehmer
Journal:  Eur J Immunol       Date:  1974-02       Impact factor: 5.532

5.  Splenic modifications induced by cyclophosphamide in C3H/He, nude, and "B" mice.

Authors:  J P Kolb; M F Poupon; G M Lespinats; D Sabolovic; F Loisillier
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

6.  The human autologous mixed lymphocyte reaction. III. Immune circuits.

Authors:  J S Smolen; T M Chused; E A Novotny; A D Steinberg
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

7.  Autologous mixed lymphocyte reaction in man. II. Autoreactive and alloreactive cells belong to two different T cell subsets.

Authors:  C Fournier; J Charreire
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

8.  The syngeneic mixed leukocyte reaction in mice. I. The cellular and genetic mechanism of the syngeneic mixed leukocyte reaction.

Authors:  U Yamashita; S Ono; H Nakamura
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

9.  The syngeneic mixed leukocyte reaction in mice. II. The I region control of suppressor T cell activity induced in the syngeneic mixed leukocyte reaction.

Authors:  U Yamashita; S Ono; H Nakamura
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

10.  The origin of cytotoxic T lymphocyte precursors (CTL-P): MHC-restricted and alloreactive CTL-P in the spleen during regeneration after a sublethal dose of cyclophosphamide (Cy).

Authors:  M Sihvola; M Hurme
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

View more
  2 in total

1.  Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.

Authors:  L S Stewart; H F Sewell; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Induction of lymphokine-activated killer-like cells by cancer chemotherapy.

Authors:  T Kiyohara; K Taniguchi; S Kubota; S Koga; T Sakuragi; Y Saitoh
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.